GoodRx Holdings Other 8-K Filing
GoodRx Holdings, Inc. announced that its financial statements for the first and second quarters of 2026 should no longer be relied upon due to an understatement of Pharma Direct revenue. The company determined that certain revenue was not recognized in accordance with ASC 606, resulting in a preliminary understatement of total revenue by approximately $29.8 million for the first half of 2026. GoodRx expects to report material weaknesses in its internal control over financial reporting and plans to file amended Forms 10-Q as soon as practicable.
- Counterparty
- KPMG LLP